Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 9/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | BRAF | P15056 | 3/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | KRAS | P01116 | 1/20 | 0.59 |
| ▸ | RAF1 | P04049 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | ARAF | P10398 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
| ▸ | FECH | P22830 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30499049 | 1.00 | CYP2C9 (0.63) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL413415 | 0.91 | CYP2C9 (0.66) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL855695 | 0.89 | CYP2C9 (0.73) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL856411 | 0.88 | BRAF (0.68) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL20399491 | 0.87 | BRAF (0.76) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL415508 | 0.87 | CYP2C9 (0.68) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL294074 | 0.87 | CYP2C9 (0.83) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL12459528 | 0.87 | CYP2C9 (0.60) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL298225 | 0.87 | CYP3A4 (0.70) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL2018645 | 0.86 | CYP2C9 (0.74) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893612-B1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC (US) | 2011-08-03 | — | — | EP | claimed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | claimed |
| EP-3284481-B1 | CELL DEATH INDUCING AGENT FOR CELLS HAVING BRAF GENE MUTATION, AGENT FOR INHIBITING PROLIFERATION OF SAID CELLS AND PHARMACEUTICAL COMPOSITION FOR TREATING PATIENT SUFFERING FROM EFFECTS OF ABNORMAL PROLIFERATION OF SAID CELLS | NITTO DENKO CORP (JP) | 2024-05-15 | — | — | EP | disclosed |
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| CN-116271056-A | Cell death inducing agent for cell having BRAF gene mutation, proliferation inhibiting agent for the cell, and pharmaceutical composition for treating disease caused by abnormal proliferation of the cell | 日东电工株式会社 | 2023-06-23 | — | — | CN | disclosed |
| US-11015224-B2 | RAF gene fusions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10570396-B2 | Cell death inducing agent for cells having BRAF gene mutation, growth suppressing agent for same cells and pharmaceutical composition for therapy of diseases caused by growth defect of same cells | NITTO DENKO CORPORATION (JP) | 2020-02-25 | — | — | US | disclosed |
| US-20180135058-A1 | CELL DEATH INDUCING AGENT FOR CELLS HAVING BRAF GENE MUTATION, GROWTH SUPPRESSING AGENT FOR SAME CELLS AND PHARMACEUTICAL COMPOSITION FOR THERAPY OF DISEASES CAUSED BY GROWTH DEFECT OF SAME CELLS | NITTO DENKO CORPORATION (JP) | 2018-05-17 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-7863289-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20080167338-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-07-10 | — | — | US | disclosed |
| US-20080167338-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-07-10 | — | — | US | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | CYP2C9 4869/4885CYP3A4 4851/4885CYP2C19 4868/4885 |
| US-20080167338-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP2C9 4746/4885CYP3A4 4658/4885CYP2C19 4579/4885 |
| US-11826365-B2 | Type II raf kinase inhibitors | BRAF, RAF1, ARAF | CYP2C9 4730/4885CYP3A4 4670/4885CYP2C19 4567/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP2C9 4746/4885CYP3A4 4658/4885CYP2C19 4579/4885 |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP2C9 4746/4885CYP3A4 4658/4885CYP2C19 4579/4885 |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CYP2C9 4730/4885CYP3A4 4670/4885CYP2C19 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.